AstraZeneca Finds Two More Potential Partners For Imfinzi
Combo Data At ESMO Supports Use With CD73 And NGK2A Inhibitors
Adding oleclumab and monalizumab to the PD-L1 inhibitor improved PFS, while another study showed improved real-world outcomes.
You may also be interested in...
Having achieved a turnaround in its R&D and commercial fortunes, AstraZeneca’s hopes the opening of a new research center will herald its next wave of novel therapies.
The immunotherapy drugs fall short of the standard set by Keytruda, but could gain some traction in non-squamous patient group.
The French firm gave back the rights to Lumoxiti on the same day the drug got a thumbs up from the CHMP after struggling to market the rare leukemia drug in the US.